Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Light chain (AL) amyloidosis is a bone marrow disorder that affects a wide range of organs
that can lead to organ dysfunction and death. Amyloid is an abnormal protein that is produced
in your bone marrow and cannot be broken down. It builds up in different organs preventing
them from working well. The most commonly affected organs are the kidneys, heart, liver,
spleen, nervous system, and digestive tract. Treatment with chemotherapy can stop the growth
of abnormal cells that produce this abnormal protein. Decrease in amyloid protein in the body
improves the function of the affected organs.
The primary purpose of this study is to determine the safest dose of the medications and how
well you tolerate them or the "maximum tolerated dose" (MTD). The study uses Ixazomib in
combination with cyclophosphamide and dexamethasone to treat people with newly diagnosed AL
amyloidosis. This combination of medications is an oral regimen that is taken over 6 cycles.
The first part of study will determine the safety of this regimen and the second part of the
study will determine how effective this combination of drugs is to treat your disease.